Navigation Links
EMD Serono, Inc. Announces Expansion with Research Site in Cambridge, Massachusetts
Date:3/30/2009

- Supports US Drug Discovery Activities in Neurodegenerative Diseases-

ROCKLAND, Mass., March 30 /PRNewswire/ -- EMD Serono, Inc. announced today that it will open a site in Cambridge, Massachusetts to support its growing Research function. The Cambridge laboratory space will accommodate EMD Serono's US drug discovery activities in neurodegenerative diseases such as multiple sclerosis (MS), which will augment the company's existing US research in oncology and fertility. EMD Serono expects to occupy the site with nearly 50 scientists across disciplines, including neurobiology, pharmacology and chemistry, to work at the location.

"This research expansion further supports EMD Serono's commitment to develop and deliver innovative therapies for patients in our areas of focus," said Fereydoun Firouz, President and CEO, EMD Serono, Inc. "EMD Serono is following our outlined strategy to broaden our research capabilities by expanding our footprint in the state of Massachusetts in close proximity to leading academic centers and qualified expertise that can be complimentary to our organization and add researchers that can grow with our team. I am proud to be delivering on our plans of continued investments to firmly establish a foothold within the state and with this expansion we confirm and reinforce our strong commitment to neurodegenerative diseases and MS research."

"EMD Serono's continued expansion in Massachusetts confirms the leadership's commitment to growing in the state and providing talented individuals with potential employment opportunities as they work to develop new treatment options for the many patients in need," said Robert Coughlin, President and CEO of Massachusetts Biotechnology Council. "This is an important announcement, during this time of economic pressure that gives some reassurance that leading biopharmaceutical companies such as EMD Serono have stability with hiring, expanding and investi
'/>"/>

SOURCE EMD Serono, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Amylin Pharmaceuticals Announces Slate of Directors for Annual Meeting of Stockholders
2. iMedica Corporation Announces the Release of Patient Relationship Manager 2009
3. Arena Pharmaceuticals Announces Positive Lorcaserin Pivotal Phase 3 Obesity Trial Results: Meets All Primary Efficacy and Safety Endpoints
4. LCA-Vision Announces Termination of Consent Solicitation and Withdrawal of Dissident Slate of Director Nominees
5. Thomson Reuters Announces 100 Top Hospitals Award Winners
6. iMedica Corporation Announces Release of Patient Relationship Manager 2009
7. KMSI Announces KMx Update That Provides eLearning, Knowledge Management and Collaboration Tools for Apple iPhone and Other Mobile Devices
8. Academy of Lymphatic Studies Announces Accelerated Hybrid Online Program
9. Human Pheromone Sciences Announces Fourth Quarter and Full Year Results
10. Nationwide Medical/Surgical Announces Availability of Tamiflu for the 2009-2010 Influenza Season
11. Zydus Pharmaceuticals (USA) Inc. Announces FDA Final Approval for the Generic Version of Topamax(R) Tablets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/21/2014)... December 21, 2014 Serious Buyer, Andrew ... 1967 Jm Morrison and the Doors International Ballroom at ... would also be the only time that Morrison's mother ... on Nov. 25, 1967. According to Hawley, “This would ... did play the Alexandria Roller Rink earlier that year ...
(Date:12/21/2014)... Columbus, OH (PRWEB) December 21, 2014 ... of men alleging heart attacks, stroke and blood clots ... continue to increase, a new study shows that the ... developing colon cancer. In a study published in the ... lead researcher, James Amos-Landgraf examined a group of male ...
(Date:12/20/2014)... 21, 2014 BambooIndustry.com is ... the business has announced its bamboo flooring promotion ... best material from certified suppliers, and offers the ... worldwide. In the current promotion, all customers can ... when they say they know BambooIndustry.com from press ...
(Date:12/20/2014)... New York, NY (PRWEB) December 20, 2014 ... ) that allege a metal-on-metal version of the ... move forward in state and federal courts, Bernstein ... in New Jersey’ Bergen County Superior Court on ... were permitted to begin deposition of plaintiffs on ...
(Date:12/20/2014)... 20, 2014 Angeldress.co.uk, the distinguished wedding ... for worldwide dress fans. The company has recently updated ... information. For the holiday season, Angeldress Blog ... wedding apparel. , Angeldress.co.uk prides itself in offering a ... of service. All the company’s outfits are very carefully ...
Breaking Medicine News(10 mins):Health News:New Low Testosterone Therapy Study Shows Male Hormone Testosterone May Contribute To Colon Cancer Reports Wright & Schulte LLC 2Health News:New Low Testosterone Therapy Study Shows Male Hormone Testosterone May Contribute To Colon Cancer Reports Wright & Schulte LLC 3Health News:New Low Testosterone Therapy Study Shows Male Hormone Testosterone May Contribute To Colon Cancer Reports Wright & Schulte LLC 4Health News:Eco-friendy Bamboo Flooring Manufacturer BambooIndustry.com Introduces Its Bamboo Flooring Promotion for 2015 2Health News:New Jersey Court Overseeing DePuy Pinnacle Hip Lawsuits Issues New Order, Bernstein Liebhard LLP Reports 2Health News:New Jersey Court Overseeing DePuy Pinnacle Hip Lawsuits Issues New Order, Bernstein Liebhard LLP Reports 3Health News:New Jersey Court Overseeing DePuy Pinnacle Hip Lawsuits Issues New Order, Bernstein Liebhard LLP Reports 4Health News:Trendy Professional Wedding Apparel Recommended by Angeldress Blog 2
... Oct. 24 (HealthDay News) -- Roughly 10 percent of Americans ... that doing so increases their risk for three common skin ... In conducting the study, researchers tracked the tanning bed ... high school and college, and then when the women were ...
... team led by scientists from The University of Texas MD ... their quest to map the vast blood vessel network of ... of Oct. 24 in the Proceedings of the National ... the goal of using the vascular system to personalize cancer ...
... Furlong founded Parent Project Muscular Dystrophy (PPMD) in 1995 to ... dystrophy with both resources and hope. Now, Furlong has blazed ... She has spearheaded a partnership between PPMD and the Public ... Currents: Muscular Dystrophy, this month. The story of the partnership ...
... Jenifer Goodwin HealthDay Reporter , MONDAY, Oct. 24 ... the airways of children with autism that she says may ... While examining children with autism who came in for a ... can see down into the windpipe and the airways that ...
... related macular degeneration (AMD) is the leading cause of ... identified several relatively common genetic variants which together predict ... number of persons without the disease also have these ... able to clearly show a specific rare mutation called ...
... University,s Office of Intellectual Property and Commercialization and ... institution,s faculty and researchers for technologies they have ... inventors. Faculty recognized for these achievements represent ... of Applied and Natural Sciences, College of Liberal ...
Cached Medicine News:Health News:More Evidence Links Tanning Beds to Higher Skin Cancer Risk 2Health News:Blood vessel mapping reveals 4 new 'ZIP codes' 2Health News:Blood vessel mapping reveals 4 new 'ZIP codes' 3Health News:Patient advocacy groups turn to open-access publishing to advance research quest 2Health News:Could Airway Abnormality Point to Autism? 2Health News:Could Airway Abnormality Point to Autism? 3Health News:Researchers ID genetic mutation associated with high risk of age-related macular degeneration 2Health News:Louisiana Tech University recognizes innovators, inventors 2Health News:Louisiana Tech University recognizes innovators, inventors 3
(Date:12/19/2014)... INDIANAPOLIS and LYON, France ... (NYSE: LLY ) and Adocia (Euronext Paris: ... focused on developing an ultra-rapid insulin, known as BioChaperone ... type 2 diabetes. BioChaperone Lispro relies on Adocia,s proprietary ... Lilly and Adocia will develop BioChaperone Lispro ...
(Date:12/17/2014)... , Dec. 17, 2014 Royal Philips ... Corporation (NASDAQ: VOLC ), a global leader in ... that they have entered into a definitive merger agreement. Pursuant ... acquire all of the issued and outstanding shares of Volcano ... price of USD 1 billion (approx. EUR 800 million), to ...
(Date:12/17/2014)... -- Revenue and earnings above the previous year ... In the past 2013/14 fiscal year (ended 30 ... EUR 4.287 billion (last year: EUR 4.190 billion) despite unfavorable ... 360 million. "Overall, 2013/14 was a successful fiscal year for ... and CEO of Carl Zeiss AG. "Thanks to our broad ...
Breaking Medicine Technology:Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology 2Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology 3Philips to acquire Volcano to expand global leadership position in image-guided therapy market 2Philips to acquire Volcano to expand global leadership position in image-guided therapy market 3Philips to acquire Volcano to expand global leadership position in image-guided therapy market 4Philips to acquire Volcano to expand global leadership position in image-guided therapy market 5Philips to acquire Volcano to expand global leadership position in image-guided therapy market 6Philips to acquire Volcano to expand global leadership position in image-guided therapy market 7Philips to acquire Volcano to expand global leadership position in image-guided therapy market 8ZEISS Asserts its Position in Difficult Environment 2
... May 21, 2007/PRNewswire-FirstCall/ -- Bristol-Myers,Squibb Company (NYSE: ... which showed that treatment with Baraclude (entecavir),demonstrated ... 48 weeks,-- a result that was also ... These data from an open-label, randomized viral ...
... -- Data presented,today at a major medical meeting ... for five days is as,effective as standard therapy ... treatment of complicated urinary tract infections,(cUTI) and acute ... markets LEVAQUIN in the,U.S., presented the data during ...
Cached Medicine Technology:Baraclude (Entecavir) Treatment Demonstrated Greater Viral Load,Reduction Compared to Adefovir at 48 Weeks in Study of,Antiviral-Naive Chronic Hepatitis B E-Antigen Positive Patients 2Baraclude (Entecavir) Treatment Demonstrated Greater Viral Load,Reduction Compared to Adefovir at 48 Weeks in Study of,Antiviral-Naive Chronic Hepatitis B E-Antigen Positive Patients 3Baraclude (Entecavir) Treatment Demonstrated Greater Viral Load,Reduction Compared to Adefovir at 48 Weeks in Study of,Antiviral-Naive Chronic Hepatitis B E-Antigen Positive Patients 4Baraclude (Entecavir) Treatment Demonstrated Greater Viral Load,Reduction Compared to Adefovir at 48 Weeks in Study of,Antiviral-Naive Chronic Hepatitis B E-Antigen Positive Patients 5Baraclude (Entecavir) Treatment Demonstrated Greater Viral Load,Reduction Compared to Adefovir at 48 Weeks in Study of,Antiviral-Naive Chronic Hepatitis B E-Antigen Positive Patients 6Five Days of LEVAQUIN(R) as Effective as 10 Days of Ciprofloxacin,in Complicated Urinary Tract Infections and Acute Pyelonephritis 2Five Days of LEVAQUIN(R) as Effective as 10 Days of Ciprofloxacin,in Complicated Urinary Tract Infections and Acute Pyelonephritis 3Five Days of LEVAQUIN(R) as Effective as 10 Days of Ciprofloxacin,in Complicated Urinary Tract Infections and Acute Pyelonephritis 4
... tip is specially rounded, extra ... wound and manipulation in the ... flexible tubing 25cm, ID - ... annular rings start .85mm ...
For administering anesthetic agents into the posterior sub-Tenon's space 20G x 1in (.90 x 25mm)...
... This all digital single plane C-arm angiography ... cardiac imaging performance and an expansive range ... cardiac angiography to ECG triggered. ... Detector technology,State of the art dynamic Flat ...
For diagnostic and operative treatment of hand and wrist bones. The use of this distraction device allows fracture reduction or widening of the space between bones....
Medicine Products: